ES2291899T3 - Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina. - Google Patents

Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina. Download PDF

Info

Publication number
ES2291899T3
ES2291899T3 ES04743565T ES04743565T ES2291899T3 ES 2291899 T3 ES2291899 T3 ES 2291899T3 ES 04743565 T ES04743565 T ES 04743565T ES 04743565 T ES04743565 T ES 04743565T ES 2291899 T3 ES2291899 T3 ES 2291899T3
Authority
ES
Spain
Prior art keywords
human
oatp
rosuvastatin
statin
baselineskip
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04743565T
Other languages
English (en)
Spanish (es)
Inventor
Helen Jean c/o AstraZeneca R & D AMBROSE
Ruth c/o AstraZeneca R & D MARCH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Application granted granted Critical
Publication of ES2291899T3 publication Critical patent/ES2291899T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Semiconductor Lasers (AREA)
ES04743565T 2003-07-26 2004-07-26 Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina. Expired - Lifetime ES2291899T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0317592.4A GB0317592D0 (en) 2003-07-26 2003-07-26 Method
GB0317592 2003-07-26

Publications (1)

Publication Number Publication Date
ES2291899T3 true ES2291899T3 (es) 2008-03-01

Family

ID=27772801

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04743565T Expired - Lifetime ES2291899T3 (es) 2003-07-26 2004-07-26 Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina.

Country Status (12)

Country Link
US (1) US7700277B2 (enExample)
EP (1) EP1651774B1 (enExample)
JP (1) JP4166257B2 (enExample)
AT (1) ATE373730T1 (enExample)
CY (1) CY1107801T1 (enExample)
DE (1) DE602004009083T2 (enExample)
DK (1) DK1651774T3 (enExample)
ES (1) ES2291899T3 (enExample)
GB (1) GB0317592D0 (enExample)
PL (1) PL1651774T3 (enExample)
PT (1) PT1651774E (enExample)
WO (1) WO2005012566A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1784504A2 (en) * 2004-07-21 2007-05-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) Oatp-c gene c463a polymorphism underlies variable response of statin therapy
CN102016073A (zh) 2008-02-29 2011-04-13 Isis创新有限公司 诊断方法
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
WO2013056087A2 (en) * 2011-10-13 2013-04-18 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
EP3220810A4 (en) 2014-11-17 2018-05-16 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment
US10572811B2 (en) 2015-01-29 2020-02-25 Splunk Inc. Methods and systems for determining probabilities of occurrence for events and determining anomalous events
CA3100035A1 (en) 2018-08-27 2020-03-05 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
CN110904215A (zh) * 2019-12-16 2020-03-24 西安和合医学检验所有限公司 用于同步检测slco1b1基因的两个snp位点的基因多态性的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US32011A (en) * 1861-04-09 Coffee-pot
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
USRE32011E (en) 1981-12-14 1985-10-22 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
IE61148B1 (en) 1988-03-10 1994-10-05 Ici Plc Method of detecting nucleotide sequences
GB8902689D0 (en) 1989-02-07 1989-03-30 Ici Plc Assay method
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
CA2176348C (en) 1993-11-12 2004-11-02 Sanjay Tyagi Hybridization probes for nucleic acid detection, universal stems, methods and kits
WO2000008157A2 (en) 1998-08-07 2000-02-17 Axys Pharmaceuticals, Inc. Human anion transporter genes atnov
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds

Also Published As

Publication number Publication date
WO2005012566A3 (en) 2005-06-16
US7700277B2 (en) 2010-04-20
WO2005012566A2 (en) 2005-02-10
EP1651774B1 (en) 2007-09-19
DE602004009083T2 (de) 2008-06-19
DE602004009083D1 (de) 2007-10-31
ATE373730T1 (de) 2007-10-15
EP1651774A2 (en) 2006-05-03
DK1651774T3 (da) 2008-01-07
PL1651774T3 (pl) 2007-12-31
JP4166257B2 (ja) 2008-10-15
PT1651774E (pt) 2007-11-16
US20070031838A1 (en) 2007-02-08
GB0317592D0 (en) 2003-08-27
JP2007500005A (ja) 2007-01-11
CY1107801T1 (el) 2013-06-19

Similar Documents

Publication Publication Date Title
JP6839779B2 (ja) スタチンの応答および心血管疾患に関連する遺伝子多型、その検出方法ならびに使用
Gloyn et al. Association studies of variants in promoter and coding regions of beta‐cell ATP‐sensitive K‐channel genes SUR1 and Kir6. 2 with Type 2 diabetes mellitus (UKPDS 53)
Viel et al. A sequence variation scan of the coagulation factor VIII (FVIII) structural gene and associations with plasma FVIII activity levels
EP2789695B1 (en) Anti-Alzheimer's disease treatment of subjects identified by detecting the presence of a genetic variant in the TOMM40 gene at rs 10524523
Hemauer et al. Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms
Austin et al. Association of apolipoprotein A5 variants with LDL particle size and triglyceride in Japanese Americans
Stanković et al. Angiotensin II type 1 receptor gene polymorphism and essential hypertension in Serbian population
ES2291899T3 (es) Uso de polmorfismos en oatp-c humano asociados con un efecto sobre la farmacocinetica de la estatina en seres humanos en terapia que usa estatina.
ES2252159T3 (es) Polimorfismos en el gen humano del transportador de anion organico c (oatp-c).
Xiao et al. Single‐nucleotide polymorphism rs13426236 contributes to an increased prostate cancer risk via regulating MLPH splicing variant 4
AU2003266967A1 (en) Methods for the treatment of dementia based on apo e genotype
WO2010102387A1 (en) Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis
Bruikman et al. Genetic variants in SUSD2 are associated with the risk of ischemic heart disease
JP5601685B2 (ja) Ａｐｏ（ａ）遺伝子における多型はアセチルサリチル酸治療に対する応答性を予測する
Guillén et al. Identification of novel SLC3A1 gene mutations in Spanish cystinuria families and association with clinical phenotypes
JP2010528262A5 (enExample)
US20080070248A1 (en) Methods for Predicting Therapeutic Response to Agents Acting on the Growth Hormone Receptor
Feng et al. Sequence variants of the POMC gene and their associations with body composition in children
US20060183146A1 (en) Genetic markers in the HLA-C gene associated with an adverse hematological response to drugs
US20060177860A1 (en) Genetic markers in the HLA-DQBI gene associated with an adverse hematological response to drugs
US20090149428A1 (en) Methods for Assessing the Predisposition or Susceptibility to COPD
WO2003106708A1 (en) Methods for the detection of polymorphisms in the human oatpf gene
WO2005045000A2 (en) Estrogen receptor gene variation and disease
US20040171010A1 (en) Methods
US20040171004A1 (en) Chemical compounds